Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.43 |
| ▸ | OGA | O60502 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884626 | 0.93 | CXCR4 (0.58) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL9884884 | 0.93 | CXCR4 (0.58) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL9884624 | 0.93 | CXCR4 (0.58) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL9884619 | 0.93 | CXCR4 (0.58) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL9884622 | 0.82 | CXCR4 (0.51) | CXCR4HRH4OGAHRH3 | |
| SCHEMBL9884621 | 0.79 | CXCR4 (0.43) | CXCR4HRH4 | |
| SCHEMBL9884620 | 0.78 | CXCR4 (0.56) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL17733674 | 0.78 | CXCR4 (0.42) | CXCR4HRH4OGAHRH3 | |
| SCHEMBL9884885 | 0.77 | CXCR4 (0.76) | CXCR4HRH4OGAHRH3ADRA2B | |
| SCHEMBL9884886 | 0.77 | CXCR4 (0.76) | CXCR4HRH4OGAHRH3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | CXCR4 247/4885HRH4 1860/4885OGA 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.